While some enjoyed a restful summer vacation, the Federal Circuit was hard at work considering issues on remand from the Supreme Court in Association for Molecular Pathology v. United States Patent and Trademark Office. Despite the court’s Aug. 20 decision, more questions than answers may remain as to the patent eligibility of inventions based on or derived from naturally occurring DNA sequences under 35 U.S.C. § 101. This is particularly true given the entrenched views of those on either side of the debate.
Read the full article by clicking the link below.
The Federal Circuit Reaffirms the Patent Eligibility of Certain Inventive Products and Methods Based on Human DNA Sequences: What Will the Supreme Court Say About That?
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.